Načítá se...

Denosumab in Postmenopausal Osteoporosis: What the Clinician Needs to Know

Denosumab is a subcutaneously (SC) administered investigational fully human monoclonal antibody to receptor activator of nuclear factor-kB ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the format...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Lewiecki, E. Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2009
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382669/
https://ncbi.nlm.nih.gov/pubmed/22870424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X09343221
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!